RISK OF HEART FAILURE HOSPITALIZATION OR DEATH FOLLOWING NON-CARDIOVASCULAR HOSPITALIZATION IN PATIENTS WITH MILDLY SYMPTOMATIC HEART FAILURE TREATED WITH CARDIAC RESYNCHRONIZATION THERAPY  by Hansen, Eric D. et al.
Heart Failure
E670
JACC March 12, 2013
Volume 61, Issue 10
risk of hearT failure hospiTalizaTion or deaTh following non-cardiovascular 
hospiTalizaTion in paTienTs wiTh mildly sympTomaTic hearT failure TreaTed wiTh cardiac 
resynchronizaTion Therapy
Moderated Poster Contributions
Poster Sessions, Expo North
Sunday, March 10, 2013, 9:45 a.m.-10:30 a.m.
Session Title: Insights into Cardiac Resynchronization and Device Therapies in Heart Failure
Abstract Category: 15. Heart Failure: Clinical
Presentation Number: 1219M-267
Authors: Eric D. Hansen, Valentina Kutyifa, Arthur Moss, Scott McNitt, Ilan Goldenberg, Wojciech Zareba, University of Rochester Medical Center, 
Rochester, NY, USA
Background: Heart failure hospitalizations are a known risk factor for future heart failure events and death in patients with cardiac disease. 
However, less is known about the risk for future heart failure events or death in patients hospitalized for non-cardiac reasons.
methods: We examined the risk for heart failure or death, whichever comes first, among 1,025 CRT-D patients with left ventricular dysfunction and 
QRS >130 ms with NYHA Class I or II symptoms enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization 
Therapy (MADIT-CRT). Multivariate analysis was used to assess the risk of heart failure or death following first cardiovascular hospitalization (CVH) 
and first non-cardiovascular (Non-CVH) hospitalizations in the CRT-D arm of the trial.
results: In multivariate analysis, first CVH and first Non-CVH were independently associated with an increase in the risk of heart failure or death 
(HR=3.50, and HR=2.24, respectively p<0.001) when compared to no hospitalization in the CRT-arm of MADIT-CRT (Fig).
conclusions: Our findings indicate that non-cardiac hospitalizations confer a meaningful and significant risk for heart failure/death in patients 
treated with cardiac resynchronization therapy.
 
